Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02273973
Registration number
NCT02273973
Ethics application status
Date submitted
22/10/2014
Date registered
24/10/2014
Date last updated
21/05/2018
Titles & IDs
Public title
A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)
Query!
Scientific title
A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer
Query!
Secondary ID [1]
0
0
2013-000568-28
Query!
Secondary ID [2]
0
0
GO28888
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Letrozole
Other interventions - Placebo
Treatment: Drugs - Taselisib
Placebo Comparator: Letrozole + Placebo - Participants will receive 2.5 mg letrozole tablets orally QD along with placebo on a 5-days-on/2-days-off schedule for a total of 16 weeks.
Experimental: Letrozole + Taselisib - Participants will receive 2.5 milligrams (mg) letrozole tablets orally once daily (QD) along with taselisib tablets at 4 mg (two 2 mg tablets) orally on a 5 days-on/2 days-off schedule for a total of 16 weeks.
Treatment: Drugs: Letrozole
Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
Other interventions: Placebo
Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
Treatment: Drugs: Taselisib
Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Objective Response (OR) by Centrally Assessed Breast Magnetic Resonance Imaging (MRI) Via Modified Response Evaluation Criteria in Solid Tumors (mRECIST) Version 1.1
Query!
Assessment method [1]
0
0
Objective response rate (ORR) was defined as proportion of participants achieving complete response (CR) or partial response (PR). As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [1]
0
0
From Baseline to 16 weeks
Query!
Primary outcome [2]
0
0
Percentage of Participants With Total Pathologic Complete Response (Total pCR), Defined as Having pCR in Both Breast and Axilla, Using American Joint Committee on Cancer (AJCC) Staging System
Query!
Assessment method [2]
0
0
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes ( i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition).
Query!
Timepoint [2]
0
0
From Baseline to 16 weeks
Query!
Primary outcome [3]
0
0
Percentage of Participants With OR by Centrally Assessed Breast MRI Via mRECIST Version 1.1 in Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha (PIK3CA) Mutant (MT) Participants
Query!
Assessment method [3]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [3]
0
0
From Baseline to 16 weeks
Query!
Primary outcome [4]
0
0
Percentage of Participants With Total pCR , Defined as Having pCR in Both Breast and Axilla, Using AJCC Staging System in PIK3CA MT Participants
Query!
Assessment method [4]
0
0
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes (i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition).
Query!
Timepoint [4]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [1]
0
0
Percentage of Participants With OR by Centrally Assessed Breast MRI Via mRECIST Version 1.1 in PIK3CA Wildtype (WT) Participants
Query!
Assessment method [1]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [1]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Total pCR Defined as Having pCR in Both Breast and Axilla, Using AJCC Staging System in PIK3CA WT Participants
Query!
Assessment method [2]
0
0
Total pCR was assessed by local pathology review on samples taken at surgery following completion of neoadjuvant therapy. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes (i.e., ypT0/Tis, ypN0 in the AJCC staging system, 7th edition).
Query!
Timepoint [2]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [3]
0
0
Percentage of Participants With OR by Breast Ultrasound Via mRECIST Version 1.1 in PIK3CA MT Participants
Query!
Assessment method [3]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [3]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [4]
0
0
Percentage of Participants With OR by Breast Ultrasound Via mRECIST Version 1.1 in PIK3CA WT Participants
Query!
Assessment method [4]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [4]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [5]
0
0
Percentage of Participants With OR by Mammography Via mRECIST Version 1.1 in PIK3CA MT Participants
Query!
Assessment method [5]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [5]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants With OR by Mammography Via mRECIST Version 1.1 in PIK3CA WT Participants
Query!
Assessment method [6]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [6]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [7]
0
0
Percentage of Participants With OR by Clinical Breast Exam (Palpation) Via mRECIST Version 1.1 in PIK3CA MT Participants
Query!
Assessment method [7]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [7]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [8]
0
0
Percentage of Participants With OR by Clinical Breast Exam (Palpation) Via mRECIST Version 1.1 in PIK3CA WT Participants
Query!
Assessment method [8]
0
0
ORR was defined as proportion of participants achieving CR or PR. As per modified RECIST v1.1, CR: disappearance of all target lesions, PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Query!
Timepoint [8]
0
0
From Baseline to 16 weeks
Query!
Secondary outcome [9]
0
0
Central Assessments of Changes in Ki67 Levels
Query!
Assessment method [9]
0
0
Ki67 is a prognostic marker and is used to evaluate the proliferative activity of breast cancer.
Query!
Timepoint [9]
0
0
From Baseline to Week 3 and Surgery (Weeks 17-18); and Week 3 to Surgery (Weeks 17-18)
Query!
Secondary outcome [10]
0
0
Preoperative Endocrine Prognostic Index (PEPI ) Score
Query!
Assessment method [10]
0
0
To obtain the PEPI score, risk points for relapse-free survival (RFS) and breast cancer-specific survival (BCSS) are assigned depending on the hazard ratio (HR) from the multivariable analysis. The total PEPI score assigned to each participant is the sum of the risk points derived from the primary tumor (pT) stage, regional lymph nodes (pN) stage, Ki67 level, and estrogen receptor status of the surgical specimen. A HR in the range of 1 to 2 receives one risk point; a HR in the 2 to 2.5 range, two risk points; a HR greater than 2.5, three risk points. The total risk point score for each participant is the sum of all the risk points accumulated from the four factors in the model, ranges from 0 (best possible outcome) to 12 (worst possible outcome).
Query!
Timepoint [10]
0
0
Week 16
Query!
Secondary outcome [11]
0
0
Percent Change From Baseline to Surgery in Enhancing Tumor Volume as Measured by Breast MRI
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
From Baseline to Surgery (Weeks 17-18)
Query!
Secondary outcome [12]
0
0
Mean Score for Health-Related Quality of Life Measured by the European Organization for Research C30 (EORTC QLQ-C30)
Query!
Assessment method [12]
0
0
EORTC QLQ-C30 is a cancer-specific instrument with 30 questions used to assess the overall quality of life (QOL) in cancer participants. The first 28 questions used a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much) for evaluating 5 functional scales (physical, role, social, cognitive, emotional), 8 symptom scales/items (diarrhea, fatigue, dyspnea, appetite loss, insomnia, nausea and vomiting [N/V], constipation, and pain) and a single item (financial difficulties). The last 2 questions represented the participant's assessment of overall health and quality of life, used 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 global scores were linearly transformed on a scale of 0 to 100, with a high score indicating better QOL. Negative change from Baseline values indicated deterioration in QOL or functioning and positive values indicated improvement. Here, Post surgery= PS.
Query!
Timepoint [12]
0
0
Weeks 1, 5, 9, 13, 16, 4-week Post-Surgery
Query!
Secondary outcome [13]
0
0
Mean Score for Treatment of Cancer Quality of Life Questionnaire BR23 (QLQ-BR23)
Query!
Assessment method [13]
0
0
EORTC-QLQ-BR23 is a 23-item breast cancer-specific companion module to the EORTC-QLQ-C30 and consists of four functional scales (body image, sexual enjoyment, sexual functioning, future perspective [FP]) and four symptom scales (systemic side effects [SE], upset by hair loss, arm symptoms, breast symptoms). Questions used 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0-100 scale. High score for functional scale indicated high/better level of functioning/healthy functioning. Negative change from Baseline indicated deterioration in QOL and positive change from Baseline indicated an improvement in QOL. Here, Post surgery= PS.
Query!
Timepoint [13]
0
0
Weeks 1, 5, 9, 13, 16, 4-week Post-Surgery
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [14]
0
0
An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Query!
Timepoint [14]
0
0
Baseline up to 22 weeks
Query!
Eligibility
Key inclusion criteria
- Female participants
- Postmenopausal status
- Histologically confirmed invasive breast carcinoma, with all of the following
characteristics: (i) Primary tumor greater than or equal to (>/=) 2 centimeters (cm)
in largest diameter (cT1-3) by MRI; (ii) Stage I to operable Stage III breast cancer;
(iii) Documented absence of distant metastases (M0)
- Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative
(HER2-) breast cancer
- Breast cancer eligible for primary surgery
- Tumor tissue from formalin-fixed paraffin-embedded cores (FFPE) core biopsy of breast
primary tumor that is confirmed as evaluable for phosphatidylinositol-4,5-bisphosphate
3-kinase, catalytic subunit alpha (PIK3CA) mutation status by central histopathology
laboratory
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Fasting glucose less than or equal to (</=) 125 milligrams per deciliter (mg/dL)
- Adequate hematological, renal, and hepatic function
- Absence of any psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule
- Ability and willingness to comply with study visits, treatment, testing, and to comply
with the protocol, in the investigator's judgment
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Any prior treatment for primary invasive breast cancer
- Participants with cT4 or cN3 stage breast tumors
- Bilateral invasive, multicentric, or metastatic breast cancer
- Participants who have undergone excisional biopsy of primary tumor and/or axillary
lymph nodes or sentinel lymph node biopsy
- Type 1 or 2 diabetes requiring antihyperglycemic medication
- Inability or unwillingness to swallow pills
- Malabsorption syndrome or other condition that would interfere with enteric absorption
- History of prior or currently active small or large intestine inflammation (such as
Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI)
toxicity requires prior approval from the Medical Monitor.
- Congenital long QT syndrome or QT interval corrected using Fridericia's formula (QTcF)
>470 milliseconds (msec)
- Diffusing capacity of the lungs for carbon monoxide (DLCO) <60% of the predicted
values
- Clinically significant (i.e., active) cardiovascular disease, uncontrolled
hypertension, unstable angina, history of myocardial infarction, cardiac failure class
II-IV
- Any contraindication to MRI examination
- Active infection requiring intravenous antibiotics
- Participants requiring any daily supplemental oxygen
- Clinically significant history of liver disease, including viral or other known
hepatitis, current alcohol abuse, or cirrhosis
- Any other diseases, active or uncontrolled pulmonary dysfunction, metabolic
dysfunction, physical examination finding, or clinical laboratory finding giving
reasonable suspicion of a disease or condition that contraindicates the use of an
investigational drug, that may affect the interpretation of the results, or renders
the participants at high risk from treatment complications
- Significant traumatic injury within 3 weeks prior to initiation of study treatment
- Major surgical procedure within 4 weeks prior to initiation of study treatment
- Inability to comply with study and follow-up procedures
- History of other malignancy within 5 years prior to screening, except for
appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or
Stage I uterine cancer
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
12/11/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
13/03/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
334
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Kinghorn Cancer Centre; St Vincents Hospital - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Newcastle Mater Misericordiae Hospital; Oncology - Waratah
Query!
Recruitment hospital [3]
0
0
Victorian Breast and Oncology Care - East Melbourne
Query!
Recruitment hospital [4]
0
0
Cabrini Medical Centre; Oncology - Malvern
Query!
Recruitment hospital [5]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [3]
0
0
- East Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [5]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Massachusetts
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
New Jersey
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New York
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Graz
Query!
Country [7]
0
0
Austria
Query!
State/province [7]
0
0
Innsbruck
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
Linz
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Salzburg
Query!
Country [10]
0
0
Austria
Query!
State/province [10]
0
0
St. Veit/Glan
Query!
Country [11]
0
0
Austria
Query!
State/province [11]
0
0
Wels
Query!
Country [12]
0
0
Austria
Query!
State/province [12]
0
0
Wien
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Brussels
Query!
Country [14]
0
0
Belgium
Query!
State/province [14]
0
0
Bruxelles
Query!
Country [15]
0
0
Belgium
Query!
State/province [15]
0
0
Edegem
Query!
Country [16]
0
0
Belgium
Query!
State/province [16]
0
0
Namur
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
RS
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
SC
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
SP
Query!
Country [20]
0
0
Chile
Query!
State/province [20]
0
0
Viña del Mar
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Hradec Kralove
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Olomouc
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Pardubice
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Pribram
Query!
Country [25]
0
0
El Salvador
Query!
State/province [25]
0
0
Salvador
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Clermont Ferrand
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Le Mans
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Saint Cloud
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Toulon
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Vandoeuvre-Les-Nancy
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Berlin
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Bielefeld
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Dresden
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Essen
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Gelsenkirchen
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Hamburg
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Hannover
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Lübeck
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Muenchen
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Münster
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Ulm
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Witten
Query!
Country [44]
0
0
Guatemala
Query!
State/province [44]
0
0
Guatemala City
Query!
Country [45]
0
0
Guatemala
Query!
State/province [45]
0
0
Guatemala
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Budapest
Query!
Country [47]
0
0
Hungary
Query!
State/province [47]
0
0
Debrecen
Query!
Country [48]
0
0
Hungary
Query!
State/province [48]
0
0
Kecskemet
Query!
Country [49]
0
0
Hungary
Query!
State/province [49]
0
0
Miskolc
Query!
Country [50]
0
0
Hungary
Query!
State/province [50]
0
0
Szeged
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Emilia-Romagna
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Liguria
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Lombardia
Query!
Country [54]
0
0
Korea, Republic of
Query!
State/province [54]
0
0
Gyeonggi-do
Query!
Country [55]
0
0
Korea, Republic of
Query!
State/province [55]
0
0
Seoul
Query!
Country [56]
0
0
Mexico
Query!
State/province [56]
0
0
Chihuahua
Query!
Country [57]
0
0
Mexico
Query!
State/province [57]
0
0
Distrito Federal
Query!
Country [58]
0
0
Mexico
Query!
State/province [58]
0
0
Mexico City
Query!
Country [59]
0
0
Panama
Query!
State/province [59]
0
0
Panama
Query!
Country [60]
0
0
Peru
Query!
State/province [60]
0
0
Lima
Query!
Country [61]
0
0
Poland
Query!
State/province [61]
0
0
Bydgoszcz
Query!
Country [62]
0
0
Poland
Query!
State/province [62]
0
0
Gdansk
Query!
Country [63]
0
0
Poland
Query!
State/province [63]
0
0
Lodz
Query!
Country [64]
0
0
Poland
Query!
State/province [64]
0
0
Otwock
Query!
Country [65]
0
0
Poland
Query!
State/province [65]
0
0
Poznan
Query!
Country [66]
0
0
Poland
Query!
State/province [66]
0
0
Warszawa
Query!
Country [67]
0
0
Portugal
Query!
State/province [67]
0
0
Lisboa
Query!
Country [68]
0
0
Portugal
Query!
State/province [68]
0
0
Porto
Query!
Country [69]
0
0
Spain
Query!
State/province [69]
0
0
Cordoba
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
LA Coruña
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Caceres
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Castellon
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Girona
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Jaen
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Lerida
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Madrid
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Sevilla
Query!
Country [79]
0
0
Spain
Query!
State/province [79]
0
0
Valencia
Query!
Country [80]
0
0
Switzerland
Query!
State/province [80]
0
0
Baden
Query!
Country [81]
0
0
Switzerland
Query!
State/province [81]
0
0
Chur
Query!
Country [82]
0
0
Switzerland
Query!
State/province [82]
0
0
Locarno
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Bournemouth
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Camberley
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Glasgow
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Genentech, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
SOLTI Breast Cancer Research Group
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Breast International Group
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
Austrian Breast and Colorectal Cancer Group
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a two-arm, randomized, double-blind, multicenter, pre-operative study to evaluate the
effect of combining letrozole and GDC-0032 (also known as taselisib) versus letrozole and
placebo in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth
factor receptor 2 (HER2) untreated, Stage I-III operable breast cancer. Participants will be
randomized into one of the two treatment arms with a 1:1 randomization ratio. Letrozole at
2.5 milligrams (mg) will be dosed once daily plus either Taselisib at 4 mg (two 2-mg tablets)
or placebo on a 5 days-on/ 2 days-off schedule for a total of 16 weeks.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02273973
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02273973
Download to PDF